BioPharma Resources

Drug Trial Radar · NCT07874815

Ensifentrine (MK-5884) Study for the Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in Adults With a History of Moderate or Severe Exacerbations While Receiving Standard of Care (SOC) (MK-5884-031/RPL554/ENHANCE-3)

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine (MK-5884) Versus Placebo for the Prevention of COPD Exacerbations in Adults With a History of Moderate or Severe Exacerbations While Receiving Standard of Care (ENHANCE-3)

Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 2,136 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

2,136

Planned (sponsor's estimate)

Start

Nov 2, 2026

Primary completion

Apr 29, 2029

Study completion Apr 29, 2029

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Oct 15, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of ensifentrine (MK-5884) compared with placebo for the prevention of moderate and severe COPD exacerbation in adults with COPD and a history of exacerbations while receiving SOC treatment. The study will also evaluate the efficacy of ensifentrine compared with placebo in improving lung function, improving health related quality of life, and preventing severe exacerbations.

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

  • EnsifentrineDrug

    Delivered twice daily by oral inhalation via a standard jet nebulizer

  • PlaceboOther

    Placebo matched to ensifentrine delivered twice daily by oral inhalation via a standard jet nebulizer

  • Standard of Care (SOC)Drug

    Background treatment of LAMA/LABA/ICS or LAMA/LABA (if ICS is not appropriate) administered per product approved label delivered by oral inhalation as part of standard of care

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized Rate of Adjudicated Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) ExacerbationsTime frame: Up to 52 Weeks

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Family First Medical Research Center ( Site 4458)

    Hialeah Gardens, Florida · Recruiting

  • Advanced Pulmonary Research Institute ( Site 4427)

    Loxahatchee Groves, Florida · Recruiting

  • Velocity Clinical Research ( Site 4464)

    Valparaiso, Indiana · Recruiting

  • CHEAR Center LLC ( Site 4407)

    The Bronx, New York · Recruiting

  • Lowcountry Lung & Critical Care, PA ( Site 4413)

    Charleston, South Carolina · Recruiting

  • M3 Wake Research, Inc. ( Site 4440)

    Chattanooga, Tennessee · Recruiting

  • Victoria Clinical Research Group ( Site 4430)

    Victoria, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.